CompletedPHASE2, PHASE3NCT00460096

Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency

Studying Alpha-1-antitrypsin deficiency

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Kamada, Ltd.
Principal Investigator: Robert A Sandhaus, M.D.
National Jewish Health
Intervention: Kamada-API(drug)
Enrollment: 50 enrolled
Eligibility: 18 years · All sexes
Timeline: 2007 – 2007

Study locations (3)

National Jewish Medical and Research Center, Denver, Colorado, United States
University of Florida School of Medicine, Gainesville, Florida, United States
The University of Texas Health Center at Tyler, Tyler, Texas, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00460096 on ClinicalTrials.gov

Other trials for Alpha-1-antitrypsin deficiency

Additional recruiting or active studies for the same condition.

See all trials for Alpha-1-antitrypsin deficiency →

← Back to all trials